drugset / Trial / NCT03661528

Trial of Andexanet Alfa in ICrH Patients Receiving an Oral FXa Inhibitor

NCT03661528

Phase 4 Completed 530 enrolled Alexion Pharmaceuticals, Inc.
RandomizedParallel-groupSingle-blindTreatment

Summary

Randomized, controlled clinical trial evaluating the efficacy and safety of andexanet alfa versus usual care in patients with intracranial hemorrhage anticoagulated with a direct oral FXa anticoagulant

Timeline

Start
2019-06-06
Primary completion
2023-05-27
Completion
2023-08-09

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Andexanet alfa Protein / enzyme biologic